Ashland's 15min chart: MACD Death Cross and KDJ Death Cross triggered.

Ashland's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross, as of 09/19/2025 at 09:45. This technical indicator suggests that the stock price has the potential to continue declining, and momentum is shifting towards the downside, potentially leading to further decreases in the stock's value.

United Guardian Inc. has released its second-quarter 2025 report, highlighting the company's performance amidst ongoing tariff challenges. The report, addressed to stockholders, provides insights into the company's financial health and strategic initiatives.

The company reported a decrease in sales and net income for the second quarter, with sales dropping from $3,390,205 in 2024 to $2,838,225 in 2025, and net income decreasing from $956,225 ($0.21 per share) to $626,826 ($0.14 per share) United Guardian : 2nd Quarter 2025 Report to Stockholders^[1]. The primary reasons for this decline were softer demand for cosmetic products in Asia, particularly due to the negative impact of tariffs, and the reduction in orders from its largest marketing partner, Ashland Specialty Ingredients (ASI).

However, the company noted an increase in sales of medical lubricants and pharmaceutical products, with medical lubricant sales increasing by 12% and pharmaceutical product sales rising by 11% compared to the same period in 2024 United Guardian : 2nd Quarter 2025 Report to Stockholders^[1]. This growth was attributed to increased orders from a large customer in China and the securing of a new customer by one of its Renacidin® distributors.

United Guardian Inc. is taking several steps to mitigate the impact of tariffs and other global economic uncertainties. These include closely monitoring the supply chain, adjusting the distribution partner network, expanding its position in healthcare, developing new products for the sexual wellness market, and seeking external opportunities for growth. The company has also formed a committee to explore new growth opportunities.

Renacidin, the company's most important pharmaceutical product, remains a priority. United Guardian Inc. has allocated resources for an insurance payer outreach program to engage medical insurance companies and secure more formulary inclusions. Additionally, the company is increasing its presence in the medical lubricant market by adding a new distribution channel and developing new products.

The cosmetic ingredient market also presents growth opportunities, with the company strengthening its marketing and distribution partnerships and continuing to design new products for the skin care and hair care markets.

Looking ahead, United Guardian Inc. expects the remainder of 2025 to be profitable and is confident that its new growth initiatives will have a positive impact on sales in 2026.